Posterior Reversible Encephalopathy Syndrome (PRES) is a critical neurological condition demanding prompt recognition and accurate diagnosis, especially in complex patient scenarios. As auto repair experts at xentrydiagnosis.store, understanding PRES can draw parallels to diagnosing intricate vehicle malfunctions – requiring systematic evaluation and precise identification of underlying issues. This article provides an in-depth exploration of PRES, focusing on its diagnosis, to enhance your understanding of this treatable condition and its impact on patient outcomes.
Understanding PRES: An Overview
Posterior Reversible Encephalopathy Syndrome, also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), reversible posterior cerebral edema syndrome, or brain capillary leak syndrome, is a condition characterized by a constellation of neurological symptoms. These can include visual disturbances, seizures, headaches, and altered mental status. The hallmark of PRES diagnosis lies in its distinctive imaging features, primarily observed on MRI of the brain, often manifesting as edema in the parieto-occipital lobes. Timely diagnosis of PRES is crucial to prevent potential complications and ensure effective treatment.
Alt text: Brain MRI FLAIR image showing characteristic hyperintensities in the posterior regions consistent with PRES syndrome diagnosis.
PRES can present with a spectrum of symptoms, developing acutely or subacutely over hours to days. While often associated with acute, uncontrolled hypertension, it’s important to note that PRES can occur in various clinical contexts. The syndrome’s name reflects the typical radiographic findings of white matter edema, seen as hyperintense T2 or hypointense T1 signals on MRI, predominantly in the posterior cerebrum. While the term “reversible” suggests a benign course, it’s crucial to recognize that PRES can lead to severe complications if not promptly diagnosed and managed. The edema isn’t always confined to the posterior regions and can affect other watershed zones, thalamus, and even the anterior circulation. Furthermore, reversibility isn’t guaranteed, and delayed treatment can result in irreversible neurological damage or life-threatening conditions like cerebellar herniation.
Etiology and Risk Factors in PRES Syndrome Diagnosis
Identifying the underlying cause is paramount in Pres Syndrome Diagnosis and management. Several risk factors and triggers are associated with PRES development:
- Hypertension: Uncontrolled hypertension is the most frequently cited etiology.
- Preeclampsia and Eclampsia: Pregnancy-related hypertensive disorders are significant risk factors.
- Renal Disease: Conditions like nephrotic syndrome and renal failure can predispose individuals to PRES.
- Liver Disease: Hepatic dysfunction can contribute to PRES development.
- Chemotherapy Agents: Certain chemotherapeutic drugs, particularly platinum-based agents, gemcitabine, and regimens like CHOP/R-CHOP, are implicated.
- Immunosuppressants and Immunotherapies: Drugs such as tacrolimus, sirolimus, interferon therapies, and monoclonal antibodies like bevacizumab, pazopanib, sorafenib, and sunitinib can trigger PRES.
- Autoimmune Disorders: Conditions like hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, eosinophilic granulomatosis with polyangiitis, and systemic lupus erythematosus are associated with increased PRES risk.
- Sepsis: Systemic infection and sepsis can also precipitate PRES.
While hypertension is a common trigger, it’s crucial to understand that PRES can occur even in the absence of significantly elevated blood pressure. The specific mechanisms that determine which individuals with these risk factors will develop PRES remain an area of ongoing research.
Epidemiology of PRES
Historically, PRES was likely underdiagnosed, but increased awareness and improved imaging capabilities have led to a better understanding of its epidemiology. PRES affects individuals across all age groups, but studies suggest a higher prevalence in middle-aged females.
A retrospective study by Fugate et al., analyzing 113 PRES patients, revealed that a significant proportion (45%) had autoimmune diseases. Seizures were the most common presenting symptom (74%), followed by encephalopathy (28%), headache (26%), and visual disturbances (20%). The study identified seizures at presentation and encephalopathy as strong predictors of PRES. Recent chemotherapy exposure and underlying renal failure were also highlighted as crucial predictive factors in PRES syndrome diagnosis.
Pathophysiology: Unraveling the Mechanisms of PRES
The precise pathophysiology of PRES remains incompletely understood, but current theories center on disruptions in cerebral autoregulation. Cerebral autoregulation is the brain’s intrinsic ability to maintain constant blood flow despite fluctuations in blood pressure through vasodilation and vasoconstriction of cerebral vessels.
In the context of hypertension, when blood pressure exceeds the autoregulatory capacity (typically above 160 mmHg systolic), cerebral blood flow increases passively. This hyperperfusion can lead to increased hydrostatic pressure, disrupting the blood-brain barrier (BBB) and causing fluid extravasation into the brain tissue, resulting in vasogenic edema. The posterior circulation is thought to be more susceptible due to potentially fewer autoregulatory mechanisms compared to the anterior circulation. This hypothesis is supported by studies indicating a greater density of adrenergic perivascular fibers in the anterior cerebral circulation.
However, the hypertensive-hyperperfusion theory doesn’t fully explain all PRES cases. PRES has been observed in normotensive individuals, particularly those on cytotoxic therapies like tacrolimus. This suggests that endothelial dysfunction plays a critical role in PRES pathophysiology. Immunosuppressants and cytotoxic drugs can directly damage the endothelium, compromising the BBB and leading to edema formation, even in the absence of hypertension.
Another proposed mechanism involves ischemia due to dysregulated cerebral autoregulation leading to vasoconstriction and cytotoxic edema. While some studies have shown vasoconstriction in PRES patients, this finding is not universal, and pathological studies have not consistently demonstrated evidence of ischemia or infarction.
Furthermore, neuroinflammation, as seen in sepsis, autoimmune disorders, and metabolic disturbances, can contribute to PRES. Conditions like uremia, hypomagnesemia, and autoimmune vasculitides can promote astrogliosis, microgliosis, and endothelial activation, increasing BBB permeability and facilitating fluid extravasation.
History and Physical Examination: Clues for PRES Syndrome Diagnosis
A thorough history and physical examination are indispensable for PRES syndrome diagnosis, as it is primarily a clinical and radiographic diagnosis. Presentations can vary widely in severity and acuity. Common presenting symptoms include:
- Headache (50%)
- Encephalopathy (28%)
- Visual Disturbances (39%): Diplopia, vision loss, cortical blindness, hemianopia, quadrantanopia.
- Seizures (80%): Focal or generalized tonic-clonic seizures.
- Focal Neurological Deficits (10-15%)
Given that altered mental status can impair the patient’s ability to provide a reliable history, obtaining information from family or caregivers is crucial. While hypertension is common, a significant proportion of patients may not present with acutely elevated blood pressure. It’s theorized that the rapidity of blood pressure elevation, rather than the absolute level, might be a critical factor, similar to febrile seizures in children.
Key findings on physical examination may include:
- Visual Field Defects: Hemianopia, quadrantanopia, visual neglect.
- Cortical Blindness
- Horizontal Gaze Palsy
- Papilledema
- Signs of Seizure: Oral trauma (tongue biting), incontinence.
- Hyperreflexia
Evaluation and Diagnostic Modalities for PRES Syndrome Diagnosis
Imaging is the cornerstone of PRES syndrome diagnosis, as clinical symptoms alone are insufficient for definitive diagnosis.
-
Head CT: Crucial for excluding other neurological emergencies like intracranial hemorrhage, especially in acute presentations with altered mental status, headache, or seizures.
-
Brain MRI: The preferred imaging modality for PRES diagnosis. MRI, without contrast, is used to identify vasogenic edema, which appears as hyperintense signals on T2-weighted and FLAIR sequences and hypointense on T1-weighted sequences. The characteristic posterior (parieto-occipital) distribution is typical, but other areas can be involved. MRI helps differentiate PRES from other conditions like stroke, hypoxic-ischemic encephalopathy, and CNS vasculitis. In PRES, edema typically spares the calcarine and paramedian occipital lobes, which can be affected in posterior cerebral artery infarcts. Diffusion-weighted imaging (DWI) can further aid in differentiating PRES from stroke, typically showing hypo- or isointense signals in PRES.
Alt text: T2 FLAIR MRI of brain demonstrating vasogenic edema predominantly in the posterior cerebral hemispheres, a key feature in PRES syndrome diagnosis.
-
Vascular Imaging (CTA/MRA/MRV): Typically normal in PRES, but can be helpful in differential diagnosis. CTA or MRA can evaluate for vasculitis, which may show vasoconstriction or vasodilation patterns. MRV can rule out cerebral venous sinus thrombosis.
-
Laboratory Investigations: Essential to identify underlying etiologies. Blood work should include:
- Electrolyte evaluation (uremia, hypomagnesemia)
- Albumin levels (hypoalbuminemia)
- Protein levels (protein deficiency)
- Complete blood count and renal function tests
- Consideration of autoimmune markers if clinically indicated.
- CSF analysis: Lumbar puncture may be necessary in immunocompromised patients or those with suspected infection to rule out encephalitis (e.g., HSV encephalitis).
-
Electroencephalogram (EEG): Can be useful in patients with persistent altered mental status to detect subclinical seizures. However, EEG findings in PRES are generally non-specific.
Treatment and Management Strategies for PRES
The cornerstone of PRES treatment is identifying and managing the underlying etiology and carefully controlling hypertension.
-
Blood Pressure Management: While no specific antihypertensive regimen is established, treatment is generally recommended when blood pressure exceeds 160/110 mmHg. The target blood pressure range is typically 130-150/80-100 mmHg. Rapid blood pressure reduction should be avoided to prevent cerebral hypoperfusion and ischemia. Blood pressure should be reduced gradually, not exceeding 25% in the first 6 hours. Intravenous titratable antihypertensives like nicardipine, clevidipine, or labetalol are often used, often requiring ICU admission for close monitoring. Long-term antihypertensive management is guided by the underlying etiology and individual patient needs.
-
Seizure Management: There is no specific antiseizure medication regimen for PRES-related seizures. Common antiepileptic drugs like levetiracetam and phenytoin are frequently used in the acute phase. Antiepileptic treatment is often discontinued once PRES resolves. However, in cases of persistent epilepsy post-PRES, long-term antiepileptic therapy may be necessary.
-
Management of Underlying Etiology: Addressing the underlying cause is crucial. This may involve:
- Discontinuing or adjusting doses of offending medications (immunosuppressants, chemotherapy agents).
- Treating sepsis.
- Managing autoimmune disorders.
- Addressing electrolyte imbalances or metabolic derangements.
-
Corticosteroids: Not generally recommended for PRES. Corticosteroids have not shown clinical benefit in PRES and may even be a trigger in some cases.
Differential Diagnosis of PRES
The differential diagnosis for PRES is broad and includes:
- Intracranial Hemorrhage: Subarachnoid hemorrhage, subdural hemorrhage, intracerebral hemorrhage.
- Cerebral Venous Thrombosis
- Posterior Circulation Stroke: Ischemic or hemorrhagic stroke.
- Basilar Artery Thrombosis
- Encephalitis: Infectious (HSV encephalitis) or autoimmune encephalitis.
- Uremic Encephalopathy
- Hypoglycemia
- Toxic or Metabolic Encephalopathies
- Primary CNS Vasculitis
Prognosis and Outcomes of PRES
The prognosis for PRES is generally favorable with prompt diagnosis and treatment. Symptom improvement or resolution typically occurs within days to weeks. Visual symptoms often resolve completely, particularly with early intervention. However, residual visual deficits or persistent seizures can occur in some cases.
Delayed treatment or severe vasogenic edema can worsen the prognosis, potentially leading to ischemia and irreversible neurological damage. Brainstem involvement is also associated with a poorer prognosis. Recurrence of PRES is possible, particularly in individuals with ongoing risk factors like chronic kidney disease requiring dialysis.
Complications of Untreated PRES
If left untreated or diagnosed late, PRES can lead to significant complications:
- Focal Neurological Deficits: Resulting from ischemic injury.
- Epilepsy: Increased risk of developing seizures.
- Life-Threatening Conditions: Transforaminal cerebellar herniation, a particularly serious complication seen in children post-hematopoietic stem cell transplantation.
Deterrence and Patient Education for PRES Awareness
Early recognition and treatment are key to preventing complications and improving patient outcomes in PRES. Increased awareness and education among healthcare professionals and at-risk patient populations are crucial. Educating patients about blood pressure management and the potential neurological effects of immunosuppressants and chemotherapy can contribute to earlier detection and intervention.
Enhancing Healthcare Team Outcomes in PRES Management
Optimal management of PRES requires a collaborative, interprofessional team approach. Effective communication and coordination among physicians (neurologists, intensivists, radiologists), nurses, pharmacists, and other healthcare professionals are essential. Radiologists play a vital role in accurate PRES syndrome diagnosis through image interpretation. Neurological and critical care services must collaborate closely, particularly for managing severe hypertension and complications in the ICU. Shared decision-making, evidence-based protocols, and integrated care pathways are crucial for achieving positive neurological outcomes in patients with PRES.
Review Questions (for self-assessment and further learning)
References (as provided in the original article)
1.Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017 Aug;264(8):1608-1616. [PMC free article: PMC5533845] [PubMed: 28054130]
2.Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int. 2012 Nov-Dec;32(6):590-4. [PMC free article: PMC3524908] [PubMed: 23212858]
3.Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996 Feb 22;334(8):494-500. [PubMed: 8559202]
4.Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010 May;85(5):427-32. [PMC free article: PMC2861971] [PubMed: 20435835]
5.Cordelli DM, Masetti R, Ricci E, Toni F, Zama D, Maffei M, Gentili A, Parmeggiani A, Pession A, Franzoni E. Life-threatening complications of posterior reversible encephalopathy syndrome in children. Eur J Paediatr Neurol. 2014 Sep;18(5):632-40. [PubMed: 24814477]
6.Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998 Mar;19(3):415-7. [PMC free article: PMC8338246] [PubMed: 9541291]
7.Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006 Mar 02;354(9):980-2; discussion 980-2. [PubMed: 16514715]
8.Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006 Oct;63(10):1475-8. [PubMed: 17030665]
9.Bodkin CL, Eidelman BH. Sirolimus-induced posterior reversible encephalopathy. Neurology. 2007 Jun 05;68(23):2039-40. [PubMed: 17548556]
10.Rajasekhar A, George TJ. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist. 2007 Nov;12(11):1332-5. [PubMed: 18055853]
11.Junna MR, Rabinstein AA. Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma. J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1410-1. [PMC free article: PMC2095620] [PubMed: 18024699]
12.Garner O, Ramirez A, Iardino A. A case of posterior reversible encephalopathy syndrome associated with sepsis. BMJ Case Rep. 2018 Jul 10;2018 [PMC free article: PMC6047718] [PubMed: 29991547]
13.Chowdhary M, Kabbani AA, Tobey D, Hope TD. Posterior reversible encephalopathy syndrome in a woman with focal segmental glomerulosclerosis. Neuropsychiatr Dis Treat. 2015;11:1111-4. [PMC free article: PMC4411014] [PubMed: 25960654]
14.Sundin CS, Johnson ML. Posterior Reversible Encephalopathy Syndrome. MCN Am J Matern Child Nurs. 2018 Mar/Apr;43(2):77-82. [PubMed: 29470266]
15.Faille LD, Fieuws S, Van Paesschen W. Clinical predictors and differential diagnosis of posterior reversible encephalopathy syndrome. Acta Neurol Belg. 2017 Jun;117(2):469-475. [PMC free article: PMC5440491] [PubMed: 28144796]
16.Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1038-48. [PMC free article: PMC7976914] [PubMed: 12063238]
17.Edvinsson L, Owman C, Sjöberg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res. 1976 Oct 22;115(3):377-93. [PubMed: 184880]
18.Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008 Jun;29(6):1036-42. [PMC free article: PMC8118828] [PubMed: 18356474]
19.Ay H, Buonanno FS, Schaefer PW, Le DA, Wang B, Gonzalez RG, Koroshetz WJ. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998 Nov;51(5):1369-76. [PubMed: 9818862]
20.Mukherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology. 2001 Jun;219(3):756-65. [PubMed: 11376265]
21.Naidu K, Moodley J, Corr P, Hoffmann M. Single photon emission and cerebral computerised tomographic scan and transcranial Doppler sonographic findings in eclampsia. Br J Obstet Gynaecol. 1997 Oct;104(10):1165-72. [PubMed: 9332995]
22.Tajima Y, Isonishi K, Kashiwaba T, Tashiro K. Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT and angiography. Intern Med. 1999 Jan;38(1):54-8. [PubMed: 10052744]
23.Lanzino G, Cloft H, Hemstreet MK, West K, Alston S, Ishitani M. Reversible posterior leukoencephalopathy following organ transplantation. Description of two cases. Clin Neurol Neurosurg. 1997 Aug;99(3):222-6. [PubMed: 9350407]
24.Nwafor DC, Brichacek AL, Mohammad AS, Griffith J, Lucke-Wold BP, Benkovic SA, Geldenhuys WJ, Lockman PR, Brown CM. Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment. J Cent Nerv Syst Dis. 2019;11:1179573519840652. [PMC free article: PMC6456845] [PubMed: 31007531]
25.Marra AM, Barilaro G, Villella V, Granata M. Eosinophilic granulomatosis with polyangiitis (EGPA) and PRES: a case-based review of literature in ANCA-associated vasculitides. Rheumatol Int. 2015 Sep;35(9):1591-5. [PubMed: 25836767]
26.Dinsdale HB. Hypertensive encephalopathy. Neurol Clin. 1983 Feb;1(1):3-16. [PubMed: 6687306]
27.Lifson N, Pasquale A, Salloum G, Alpert S. Ophthalmic Manifestations of Posterior Reversible Encephalopathy Syndrome. Neuroophthalmology. 2019 Jun;43(3):180-184. [PMC free article: PMC6619982] [PubMed: 31312242]
28.Hawatmeh A, Studyvin S, Al-Halawani M, Amireh S, Thawabi M. Posterior reversible encephalopathy syndrome associated with left horizontal gaze palsy. Ann Transl Med. 2017 Mar;5(5):104. [PMC free article: PMC5360612] [PubMed: 28361069]
29.Vandenbossche G, Maquet J, Vroonen P, Lambert G, Nisolle M, Kridelka F, Emonts E. A reversible posterior leucoencephalopathy syndrome including blindness caused by preeclampsia. Facts Views Vis Obgyn. 2016 Sep;8(3):173-177. [PMC free article: PMC5172574] [PubMed: 28003872]
30.Zou LP, Liu LY, Li H, Wang YY, Liu Y, Chen J, Hu LY, Liu MJ, Zhang MN, Lu Q, Ma SF. Establishment and utility assessment of posterior reversible encephalopathy syndrome early warning scoring (PEWS) scale establishment and utility assessment of PEWS scale. BMC Neurol. 2019 Feb 21;19(1):30. [PMC free article: PMC6385440] [PubMed: 30791893]
31.Bartynski WS, Boardman JF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2008 Mar;29(3):447-55. [PMC free article: PMC8118858] [PubMed: 18079186]
32.Murray K, Amin U, Maciver S, Benbadis SR. EEG Findings in Posterior Reversible Encephalopathy Syndrome. Clin EEG Neurosci. 2019 Sep;50(5):366-369. [PubMed: 31215229]
33.Strother R, Wong H, Miller NE. Posterior Reversible Encephalopathy Syndrome Secondary to Hypertensive Encephalopathy Brought on by a MAO Inhibitor: A Case Report. J Prim Care Community Health. 2019 Jan-Dec;10:2150132719869539. [PMC free article: PMC6698996] [PubMed: 31423884]
34.Gokhale A, Kimona A, Kantor S, Prakash S, Manhas Y. Posterior Reversible Leukoencephalopathy Syndrome (PRES) in Intensive Care Unit – Case series. Indian J Crit Care Med. 2017 Nov;21(11):772-778. [PMC free article: PMC5699006] [PubMed: 29279639]
35.Spencer D. PRES-ing for Answers About Long-Term Seizure Risk in Patients With Posterior Reversible Encephalopathy Syndrome. Epilepsy Curr. 2015 Nov-Dec;15(6):317-8. [PMC free article: PMC4657768] [PubMed: 26633947]
36.Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: what’s certain, what’s new? Pract Neurol. 2011 Jun;11(3):136-44. [PubMed: 21551107]
37.Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999 May;246(5):339-46. [PubMed: 10399863]
38.Atça AÖ, Erok B, Aydoğdu S. Neuroimaging findings of posterior reversible encephalopathy syndrome (PRES) following haematopoietic stem cell transplantation in paediatric recipients. BMC Pediatr. 2021 Oct 11;21(1):445. [PMC free article: PMC8504064] [PubMed: 34629063]
Disclosure: Jaime Zelaya declares no relevant financial relationships with ineligible companies.
Disclosure: Lama Al-Khoury declares no relevant financial relationships with ineligible companies.
